相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。[89Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models
Yun Lu et al.
MOLECULES (2021)
Multiparametric Analysis of Longitudinal Quantitative MRI Data to Identify Distinct Tumor Habitats in Preclinical Models of Breast Cancer
Anum K. Syed et al.
CANCERS (2020)
Inside the hypoxic tumour: reprogramming of the DDR and radioresistance
Katheryn Begg et al.
CELL DEATH DISCOVERY (2020)
Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+breast cancer
Angela M. Jarrett et al.
MATHEMATICAL MEDICINE AND BIOLOGY-A JOURNAL OF THE IMA (2019)
Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy
Steffen Loeck et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+Breast Cancer
Anum K. Syed et al.
NEOPLASIA (2019)
Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?
Hui Wang et al.
CANCERS (2019)
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Jiani Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Long-term trastuzumab (Herceptin (R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Volkmar Mueller et al.
BMC CANCER (2018)
Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+Breast Cancer
Anna G. Sorace et al.
MOLECULAR IMAGING AND BIOLOGY (2017)
[18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis
Lien Bekaert et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements
Olivia J. Kelada et al.
MOLECULAR IMAGING AND BIOLOGY (2017)
Downregulation of DNA repair proteins and increased DNA damage in hypoxic colon cancer cells is a therapeutically exploitable vulnerability
Jennifer M. J. Jongen et al.
ONCOTARGET (2017)
Developmental and Functional Control of Natural Killer Cells by Cytokines
Yang Wu et al.
FRONTIERS IN IMMUNOLOGY (2017)
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer
Ariella B. Hanker et al.
CANCER RESEARCH (2017)
Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+breast cancer: preliminary results
Anna G. Sorace et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo
Jing Hou et al.
ONCOTARGET (2016)
Correlation of tumor characteristics derived from DCE-MRI and DW-MRI with histology in murine models of breast cancer
Stephanie L. Barnes et al.
NMR IN BIOMEDICINE (2015)
Cellular and Molecular Mechanisms Underlying Oxygen-Dependent Radiosensitivity
Chao Liu et al.
RADIATION RESEARCH (2015)
The accumulation mechanism of the hypoxia imaging probe FMISO by imaging mass spectrometry: possible involvement of low-molecular metabolites
Yukiko Masaki et al.
SCIENTIFIC REPORTS (2015)
Utility of [F-18]FLT-PET to Assess Treatment Response in Trastuzumab-Resistant and Trastuzumab-Sensitive HER2-Overexpressing Human Breast Cancer Xenografts
Jennifer G. Whisenant et al.
MOLECULAR IMAGING AND BIOLOGY (2015)
Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study
J. Jacob et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts
Jennifer G. Whisenant et al.
TRANSLATIONAL ONCOLOGY (2014)
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
Xiaomei Zhang et al.
CANCER RESEARCH (2013)
Trastuzumab: updatedmechanisms of action and resistance in breast cancer
Thuy Vu et al.
FRONTIERS IN ONCOLOGY (2012)
Prolonged expression of the γ-H2AX DNA repair biomarker correlates with excess acute and chronic toxicity from radiotherapy treatment
Emma C. Bourton et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer
Chirayu Shah et al.
CLINICAL CANCER RESEARCH (2009)
The anti-oxidant capacity of tumour glycolysis
Ulrike G. A. Sattler et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2009)
Adjuvant trastuzurnab therapy for HER2-Positive breast cancer
Mohammad Jahanzeb
CLINICAL BREAST CANCER (2008)
Cardiotoxicity profile of trastuzumab
Steven M. Ewer et al.
DRUG SAFETY (2008)
γ-H2AX as a therapeutic target for improving the efficacy of radiation therapy
J. Kao et al.
CURRENT CANCER DRUG TARGETS (2006)
Fully automated one-pot synthesis of [18F]fluoromisonidazole
GH Tang et al.
NUCLEAR MEDICINE AND BIOLOGY (2005)
Impact of tumor hypoxia and anemia on radiation therapy outcomes
LB Harrison et al.
ONCOLOGIST (2002)
分享论文
